Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis

Drug Name


Company / Licensee

Incyte / Eli Lilly

Therapy Class

JAK inhibitor

Product Description

JAK1 and JAK2 inhibitor

Current Indication

Rheumatoid arthritis

Market Sector


Current Status

NDA under review by the US FDA

Go Top